Canine glaucoma medically, although sometimes surgery is required. As the cause of primary glaucoma is often unknown, medical treatment is usually aimed at reducing the main sign of glaucoma (raised intraocular pressure) rather than at treating the cause of the disease. The aim of surgery in dogs with glaucoma is to reduce intraocular pressure. This is achieved by reducing aqueous humor production, or by improving drainage of aqueous humor from the eye. Laser surgery is often performed to selectively destroy the tissue, ciliary body, in an effort to reduce aqueous fluid production. Laser surgery can also be combined with placement of a
Minimally invasive glaucoma surgery to augment outflow to the suprachoroidal space in order to control intraocular pressure; it is indicated for the treatment of primary open-angle glaucoma. The stent is implanted through an ab interno approach and inserted into the supraciliary space (between the ciliary body and sclera), effectively creating a controlled cyclodialysis cleft, which is kept open by the device. The first clinical data on the device was presented in 2010 showed sustained IOP lowering and MIGS-like safety profile. This has been substantiated in subsequent studies in the combined setting with cataract surgery and as a stand-alone treatment for patients failing glaucoma topical